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PROGNOSTIC IMPORTANCE OF MONITORING SERUM
AMYLOID A PROTEIN (SAA) IN PATIENTS WITH CEREBRAL
INFARCTION
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SUMMARY ∑ Serum amyloid A protein (SAA) is an acute-phase plasma protein, which increases
in response to tissue damage. The aim of the study was to investigate SAA in the blood of patients
with cerebral infarction. Sixty subjects were studied, including 45 patients with cerebral infarction
and 15 controls. SAA was determined using ELISA method on days 1, 3, 7 and 14 after ischemic
stroke onset. SAA was found to increase by day 3, which was followed by a decrease if no infectious
complication occurred. The concentration of SAA was statistically significantly increased on days 1,
3, 7 and 14 (p < 0.05), however, the increase was greater in patients with severe clinical manifestati-
ons. A statistically significant SAA increase by day 14 was recorded in patients with an accompany-
ing infectious process. The study showed the concentration of SAA to depend  on the clinical sever-
ity of ischemic stroke. SAA was found to be a sensitive early indicator of possible infectious compli-
cations.
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Introduction
Acute phase proteins are synthesized by the liver as
a nonspecific response to tissue damage or infection1-3.
Serum amyloid A protein (SAA) is an acute phase pro-
tein complexed to high-density lipoproteins (HDL) as
an apoprotein (apo SAA). It is mainly found in HDL3
fraction, but small amounts can be found in other HDL
fractions as well as in low-density lipoproteins (LDL)
and very low-density lipoproteins (VLDL). SAA is the
most impressive of acute-phase proteins, increasing
within 24 h by up to 1000-fold, and resulting in displace-
ment of apo A-I, apo A-II and apo A-III proteins from
the HDL complex. Six major isoforms of SAA can be
extracted from the plasma HDL fraction of patients with
inflammatory diseases4-9. The molecular weight of SAA
is 11.4 ∑ 12.5 kDa and the protein has from 104 to 112
amino acids. In man, the protein is coded on chromo-
some 11 p. Interleukin-1(IL-1), interleukin-6 (IL-6)
and tumor necrosis factor (TNF) stimulate hepatic SAA
production10,11. The function of SAA remains unclear12.
SAA can influence lymphocytic responses to antigens,
and plays a role in cholesterol metabolism during the
course of acute inflammation13. Steinmetz found a sig-
nificant decrease of esterified cholesterol in plasma dur-
ing acute phase response due to a decreased plasma leci-
thin ∑ cholesterol acyltransferase (LCAT) activity14.
SAA induces the synthesis of collagenase and can inhibit
fever induced by IL-1 or TNF 15,16. It can suppress
thromboxin synthesis and platelet release of serotonin,
and inhibit platelet aggregation17. The acute-phase pro-
teins, apo SAA1 and apo SAA2, can be precursors of
amyloid AA peptides. These deposits are a complication
of chronic inflammatory disorders, but the role of SAA
in amyloidogenesis is still unclear4,12.  SAA has been
used in diagnosing and monitoring of different diseases,
among others myocardial infarction, bacterial and viral
infections, arthritis, and malignant disease18-20. The aim
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of this study was to evaluate SAA concentration in the
blood of patients with cerebral infarction in dependence
of the disease severity, and the effect of infectious ∑ in-
flammatory process on SAA concentration in patients
with cerebral infarction.
Patients and Methods
Sixty patients hospitalized at the Department of Neu-
rology were included in the study: 25 patients with cere-
bral infarction not complicated by infectious ∑ inflamma-
tory process; 20 patients with cerebral infarction compli-
cated by infectious ∑ inflammatory process; and 15 con-
trol group subjects. Control group (C) included 15 sub-
jects, eight women and seven men, mean age 57 years.
Patients with radicular syndrome in remission were in-
cluded in this group. In the control group, SAA concen-
tration was measured once.
The patients were divided into two groups according
to disease severity:
1. patients with cerebral infarction with less severe clini-
cal course (group E-1); and
2. patients with cerebral infarction with more severe
clinical course (group E-2).
Disease severity was assessed by use of 8-point scale
proposed by Fisher21: ∑  up to 2 points ∑ patients with no
consciousness disturbances; 1 point ∑ patients without
feeling disturbances; up to 2 points ∑ patients without
speech disturbances; and up to 3 points ∑ patients with-
out motoneuron function damages. Patients with a score
≤5 were allocated to the group with a more severe course
of cerebral infarction.
The group of patients with a less severe clinical course
of cerebral infarction not complicated by infectious ∑ in-
flammatory process (E1) comprised 13 subjects, eight
women and five men, mean age 63. The group of patients
with cerebral infarction not complicated by infectious ∑
inflammatory process with a more severe clinical course
(E2) included 12 subjects, six men and women each, mean
age 65. The group of patients with cerebral infarction
complicated by infectious ∑ inflammatory process with a
less severe clinical course (E3) had 11 subjects, six women
and five men, mean age 65, while the group of patients
with cerebral infarction complicated by infectious ∑ in-
flammatory process with a more severe clinical course
(E4) had nine subjects, five women and four men, mean
age 68. Urinary tract infection was found in 11, pneumo-
nia in seven, and inflammatory thrombotic process in
limbs in two patients. In the group of patients with cere-
bral infarction, SAA was determined on days 1, 3, 7 and
14 after the onset of disease.
Cerebral infarction was recognized on the basis of an
interview, neurologic state of patients, and finding of brain
computer tomography (CT). Cerebral infarction compli-
cated by infectious ∑ inflammatory process was recognized
on the basis of supplementary examinations (urine analysis
and inoculation, chest x-ray).
SAA was determined by ELISA (enzyme-linked im-
munosorbent assay)22 using a Cytoscreen TM Immunoas-
say kit from Biosource International. Results were statis-
tically analyzed  by Student’s t-test and analysis of va-
riance was done by use of Duncan test. Statistical signifi-
cance was considered at a level of p < 0.05.
Results
In the control group patients, SAA concentration was
determined only once in the remission period of radicu-
lar syndrome, showing a mean concentration of 2.82 ± 5.4
µg/ml. Literature reports indicate the mean concentration
of this protein in serum of healthy individuals as deter-
mined by the ELISA method to be 1-2 mg/ml, with a va-
lue dispersion of 8-10 mg/l5.
The study showed the SAA concentration in the gro-
up of patients with a less severe clinical course of cere-
bral infarction to increase by day 3 from the onset of
disease, whereafter it was found to decline. The highest
increase of SAA was recorded between days 1 and 3. The
mean SAA concentration in these patients according to
day of determination was as follows: 158.9 ± 5.2 µg/ml
on day 1; 540.9 ± 83.3 µg/ml on day 3; 404.9 ± 65.1 µg/
ml on day 7; and 236.4 ± 65.5 µg/ml on day 14. The con-
centration of SAA was statistically significantly higher
in this group of patients than in the control group of
patients on all days of determination (p < 0.05; diff.:
158.9 ± 10.3, t=54.2 on day 1; 537.7 ± 72.5, t = 23.4 on
day 3; 401.7 ± 63.9, t = 22.6 on day 7; and 233.2 ± 62.9,
t = 13.3 on day 14). In patients with a less severe clini-
cal course of cerebral infarction, differences in SAA con-
centration between days 1 and 3 (381.9 ± 84.9, t = 16.2),
days 3 and 7 (135.9 ± 133.0, t = 3.6), and days 7 and 14
(168.5 ± 82.1, t = 7.3) were statistically significant (p <
0.05) (Fig. 1).
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Fig. 1. SAA concentration ((g/ml) in patients with a less severe clini-
cal course of cerebral infarction (E1) on days 1, 3, 7 and 14.
In patients with a more severe clinical course of ce-
rebral infarction, the concentration of SAA also was on
a rise by day 3, whereafter a decline was observed. The
highest increase of SAA concentration was recorded
between days 1 and 3. According to days of determi-
nation, the mean SAA concentration was as follows:
232.3 ± 90.8 µg/ml on day 1; 585.0 ± 55.4 µg/ml on
day 3; 573.2 ± 79.8 µg/ml on day 7; and 322.4 ± 90.8
µg/ml on day 14. There was a statistically significant
difference (p < 0.05) in the SAA concentration between
days 1 and 3 (352.6 ± 116.1, t=10.5) and days 7 and 14
(245.8 ± 81.4, t = 9.5), while the difference recorded
between days 3 and 7 did not reach statistical signifi-
cance (6.9 ± 103.2, t = 0.2; p > 0.05). The concentra-
tion of SAA was statistically significantly higher in this
group of patients than in the control group of patients
on all days of determination (p < 0.05; diff.: 228.9 ±
88.3, t = 8.9 on day 1; 581.5 ± 54.3, t = 37.0 on day 3;
569.5 ± 81.0, t = 23.3 on day 7; and 318.3 ± 8.8, t =
113.2 on day 14) (Fig. 2).
Fig. 2. SAA concentration ((g/ml) in patients with a more severe
clinical course of cerebral infarction (E2) on days 1, 3, 7 and 14.
SAA concentration in patients with cerebral infarc-
tion complicated by infectious ∑ inflammatory process
was increased by day 14 from the onset of disease, with
highest increase recorded between days 1 and 3. In this
group of patients, the mean SAA concentration was
218.6 ± 60.4 µg/ml on day 1; 736.5 ± 109.6 µg/ml on
day 3; 999.9 ± 169.7 µg/ml on day 7; and 1118.8 ± 132.2
µg/ml on day 14. The concentration of SAA was statis-
tically significantly higher in this group of patients than
in the control group of patients on all days of determi-
nation (p < 0.05; diff.: 215.7 ± 61.7, t = 13.5 on day 1;
733.7 ± 108.0, t = 26.2 on day 3; 997.8 ± 171.2, t = 21.0
on day 7; and 1116.0 ± 133.8, t = 26.3 on day 14). There
was a statistically significant difference (p < 0.05) in the
SAA concentration between days 1 and 3 (510.0 ± 124.5,
t = 18.3) and days 3 and 7 (283.3 ± 201.6, t = 5.9), while
the difference recorded between days 7 and 14 did not
reach statistical significance (64.9 ± 136.5, t = 1.8; p >
0.05) (Fig. 3).
Fig. 3. SAA concentration ((g/ml) in patients with cerebral infarc-
tion complicated by infectious - inflammatory process (E3) on days
1, 3, 7 and 14.
Comparative analysis of SAA concentration in pa-
tients with cerebral infarction not complicated and com-
plicated by infectious ∑ inflammatory process showed
highest SAA concentration in patients with cerebral in-
farction not complicated by infectious ∑ inflammatory
process with a more severe clinical course and lowest
SAA concentration in patients with cerebral infarction
with a less severe course of disease on day 1. On days 3,
7 and 14 of the disease, highest SAA concentration was
recorded in patients with cerebral infarction complicated
by infectious ∑ inflammatory process, and lowest SAA
concentration in patients with cerebral infarction with
a less severe course of disease and not complicated by
infectious ∑ inflammatory process. The difference in
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tients with and without a complication of an infectious
∑ inflammatory process was especially pronounced on
day 14.
Comparative analysis of SAA concentration in pa-
tients with cerebral infarction not complicated by infec-
tious ∑ inflammatory process with a less and more severe
clinical course of disease (E1 vs E2) according to days of
determination showed statistically significant differences
(p < 0.05) on days 1 (74.1 ± 91.9, t = 2.7), 7 (161.6 ± 108.0,
t = 4.9), and 14 (71.7 ± 67.3, t = 3.3). On day 3, the diffe-
rence in SAA concentration did not reach statistical sig-
nificance (34.8 ± 86.8, t = 1.3; p > 0.05).
Comparative analysis of SAA concentration in patients
with cerebral infarction not complicated by infectious ∑
inflammatory process with a less and more severe clinical
course of disease (E1 vs E2) according to days of determi-
nation showed statistically significant differences (p < 0.05)
on days 1 (74.1 ± 91.9, t = 2.7), 7 (161.6 ± 108.0, t = 4.9),
and 14 (71.7 ± 67.3, t = 3.3). On day 3, the difference in
SAA concentration did not reach statistical signficance
(34.8 ± 86.8, t = 1.3; p > 0.05).
Comparative analysis of SAA concentration accord-
ing to days of determination between patients with cere-
bral infarction not complicated by infectious ∑ inflamma-
tory process with a less and more severe clinical course of
disease, and those with cerebral infarction complicated by
infectious ∑ inflammatory process revealed statistically
signficant differences (p < 0.05; diff. E1 vs E3: 65.2 ± 59.6,
t = 3.9 on day 1; 203.4 ± 119.6, t = 6.1 on day 3; 617.2 ±
170.0, t = 12.5 on day 7; and 912.7 ± 137.3, t = 19.9 on
day 14; and E2 vs E3: 160.7 ± 111.3, t = 5.0 on day 3;
449.5 ± 173.6, t = 8.1 on day 7; and 798.2 ± 141.5, t = 14.9
on day 14). Only the E2 vs E3 difference recorded on day
1 (14.98 ± 90.3, t = 0.5) did not reach statistical significan-
ce (p > 0.05) (Fig. 4).
Fig. 4. Comparative analysis of SAA concentration in patients with
cerebral infarction on days 1, 3, 7 and 14.
Discussion
Our own investigations showed a cerebral tissue
damage due to ischemia to result in acute phase response
inducing an SAA concentration increase in the blood of
patients. Previous studies of the acute phase SAA pat-
tern have pointed to its high responsivity in different
disease processes2-4,9,18,20. Investigations of the behav-
ioral pattern of acute phase proteins (SAA, C-reactive
protein, α1-antichymotripsin, α1-acid glycoprotein,
haptoglobin) have shown them to rise in the blood of
patients with cerebral infarction23,24. According to
Syrjanen et al.2 and Marhaug et al.18, the increase in the
concentrations of SAA and other acute phase proteins
is higher in myocardial infarction than in cerebral inf-
arction. The higher concentrations of SAA in patients
with non-complicated cerebral infarction with a more
severe clinical course, recorded in the present study in
comparison to SAA concentration in patients with non-
complicated cerebral infarction with a less severe clini-
cal course indicated a significant dependence of SAA
concentration on the patient’s clinical condition.
Marhaug and Dowton4 also report on a higher concen-
tration of SAA in patients with a more severe clinical
course of rheumatic disease. Widespread cerebral infarc-
tion foci leading to a more severe clinical course of the
disease may cause major damage to the blood ∑ brain
barrier, which may be the reason for differences in the
release of acute phase mediators and in SAA concen-
tration between patients with a less and more severe
clinical course25. Studies in patients with myocardial in-
farction showed a positive correlation between SAA con-
centration and infarction focus size18. There are no such
investigations on cerebral infarction. Syrjanen et al.2
failed to demonstrate any dependence between SAA
concentration and localization of the focus of infarction
as far as the supratentorial and subtentorial brain struc-
tures are considered. The role of infectious ∑ inflamma-
tory process in the etiopathogenesis of cerebral infarc-
tion has not yet been fully explained. Earlier studies have
pointed to a higher activity of acute phase response in
patients in whom an infectious ∑ inflammatory process
anticipated cerebral infarction or concurred during or
after the stroke period. The possible effect of vascular
inflammation during the course of infection on their
occlusion and origin of cerebral infarction has been con-
sidered2. Our studies have confirmed previous observa-
tions that the course of cerebral infarction superimposed
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phase response, expressing itself in a higher and pro-
longed elevation of SAA concentration in the patient’s
blood. In relation to this, monitoring of SAA concen-
tration in the blood of patients may be a sensitive indi-
cator of infectious ∑ inflammatory complications occur-
ring during the course of cerebral infarction. It should
be remembered that a chronic inflammatory process
causing hematologic stress syndrome, characterized
among others by elevated levels of acute phase proteins,
including serum amyloid A protein, may be the cause of
secondary amyloid in the vessel walls, which in turn re-
sults in a damage to their basal membrane12,26. Arakawa
et al.27 describe a patient with relapsing cerebral infarc-
tion episodes in the course of secondary amyloidosis con-
comitant with rheumatoid arthritis. Secondary amyloi-
dosis may be the etiologic factor for ischemic stroke, so
efficient treatment of all chronic infectious ∑ inflamma-
tory processes is of utmost importance.
Table 1. SAA concentrations in the groups of patients with cerebral infarction (µg/ml)
Group      day 1 day 3 day 7 day 14
mean±SD mean±SD mean±SD mean±SD
E1 158.96±5.24 533.22±87.71 404.90±65.09 236.39±52.41
E2 224.2±90.86 585.00±55.49 573.29±79.87 322.49±6.70
E3 193.8±25.84 683.61±179.5 956.17±148.14 1034.26±151.99
E4 243.25±66.16 770.11±75.39 1061.90±153.78 1164.01±105.37
E1 = patients with cerebral infarction not complicated by infectious - inflammatory process with less
severe clinical course; E2 = patients with cerebral infarction not complicated by infectious - inflam-
matory process with more severe clinical course; E3 = patients with cerebral infarction complicated by
infectious - inflammatory process with less severe clinical course; E4 = patients with cerebral infarc-
tion complicated by infectious - inflammatory process with more severe clinical course.
Table 2. Differences in SAA concentrations (µg/ml) in patients with cerebral
infarction between days of disease onset
Group Difference
Days 1-3 Days 3-7 Days 7-14
E1 374.26* t=2.63 128.32* t=2.48 168.51* t=2.62
E2 360.8* t=2.63 11.71 t=1.28 250.8* t=2.43
E3 489.8* t=2.90 272.56* t=2.83 78.0* t=2.31
E4 526.86* t=2.75 290.89* t=5.23 102.11 t=0.44
Student’s t-test; *statistically significant difference p<0.05
Table 3.  Comparative analysis of SAA concentration ((g/ml) between different groups of patients with cerebral infarction and
control patient group
Day Diff. Diff. Diff. Diff. Diff. Diff. Diff. Diff. Diff. Diff.
E1-E2 E1-E3 E1-E4 E2-E3 E2-E4 E3-E4 C-E1 C-E2 C-E3 C-E4
1 65.24 34.84 84.29 30.4 19.05 49.45 156.1* 221.3* 190.9* 240.4*
3 51.78 150.3* 236.8* 98.61* 185.1* 86.5* 530.4* 582.1* 680.7* 767.2*
7 168.3* 551.2* 657.0* 382.8* 488.6* 908.1* 402.0* 570.4* 953.3* 1059*
14 86.1* 797.8* 927.6* 711.7* 841.5* 129.7* 233.5* 319.6* 1031* 1161*
Duncan test, *statistically significant difference p<0.05
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Conclusions
1. In patients with cerebral infarction not complicated by
infectious ∑ inflammatory process, a statistically sig-
nificant increase of SAA concentration was observed,
which was especially pronounced on day 3 from the
onset of disease.
2. In patients with cerebral infarction complicated by in-
fectious ∑ inflammatory process with a less and more
severe clinical course, a statistically significant increase
of SAA concentration was recorded by day 14 from the
onset of disease.
3. Differences in SAA concentrations between cerebral
infarction patients with a less and more severe clini-
cal course may be helpful in monitoring the disease
process dynamics.
4. Differences in SAA concentrations between groups of
patients with cerebral infarction complicated and not
complicated by infectious ∑ inflammatory process sug-
gest that SAA may be a sensitive indicator of inflam-
matory complications occurring during the course of
the disease.
References
1. RAYNES JG, EAGLING S, Mc ADAM KP. Acute-phase pro-
tein synthesis in human hepatoma cells: differential regulation of
serum amyloid A (SAA) and haptoglobin by interleukin-1 and
interleukin-6. Clin Exp Immunol 1991;83:448-91.
2. SYRJANEN J, TEPPO AM, VALTONEN VV, IVAVAINEN M,
MAURY CPJ. Acute phase response in cerebral infarction. J Clin
Pathol 1989;42:63-8.
3. JENSEN LE, HINEY MP, SHIELDS DC, UHLAR CM,
LINDSAY AJ, WHITEHEAD AS. Acute phase proteins in Sal-
monidis: evolutionary analyses and acute phase response. J Im-
munol 1997;158:384-92.
4. MARHAUG G, DOWTON S. Serum amyloid A: an acute phase
apolipoprotein and precursor of AA amyloid. Baillieres Clin Rheu-
matol 1994; 8:553-73.
5. MARHAUG G, SLETTEN K, HUSBY G. Characterization of
amyloid related protein SAA complexed with serum lipoprotein
(APO SAA). Clin Exp Immunol 1982;50:382-9.
6. WHITEHEAD AS, De BEER MC, STEEL DM. Identification
of novel members of the serum amyloid A protein superfamily as
constitutive apolipoproteins of high density lipoprotein. J Biol
Chem 1992;267:3862-7.
7. LINDHORST E, YOUNG D, BAGSHAW W, HYLAND M,
KISILEVSKY R. Acute inflammation, acute phase serum amyloid
A and cholesterol metabolism in the mouse. Biochim Biophys Acta
1997;1339:143-54.
8. LIAO F, LUSIS AJ, BERLINER JA, FOGELMAN AM,
KINDY M, De BEER MC, De BEER F. Serum amyloid A pro-
tein family. Differential induction by oxidized lipids in mouse
strains. Arterioscler Thromb 1994;14:1475-9.
9. MARHAUG G, PERMIN H, HUSBY G. Amyloid-related se-
rum protein (SAA) as an indicator of lung infection in cystic fi-
brosis. Acta Paediatr Scand 1983;72:861-6.
10. MARINKOVIC S, JAHREIS GP, WONG GG, BAUMAN H.
IL-6 modulates the synthesis of a specific set of acute phase prote-
ins in vivo. J Immunol 1989;142:808-12.
11. DOWTON SB, PETERS CN, JESTUS J.J. Regulation of serum
amyloid A gene expression in syrian hamsters by cytokines.
Inflammation 1991;15:391-7.
12. ANCSIN JB, KISILEVSKY R. Characterization of high affinity
binding between laminin and the acute-phase protein, serum amy-
loid A. J Biol Chem 1997;272:406-13.
13. ALDO-BENSON MA, BENSON MD. SAA suppression of im-
mune response in vitro: evidence for an effect on T cell ∑ macroph-
age interaction. J Immunol 1982;126:2390-2.
14. STEINMETZ A, HOCKE G, SALE R. Influence of serum amy-
loid A on cholesterol esterification in human plasma. Biochim Bio-
phys Acta 1989;1006:173-8.
15. MITCHELL TI, COON CI, BRINCKERHOFF CE. Serum
amyloid A (SAA3) produced by rabbit synovial fibroblasts treated
with phorbol esters or interleukin-1 induces synthesis of collage-
nase and is neutralized with specific antiserum. J Clin Invest
1991:87:1177-85.
16. SHAINKIN-KESTENBAUM R, BERLYNE G, ZIMLICH-
MAN S. Acute phase protein, serum amyloid A, inhibits IL-1 and
TNF-induced fever and hypothalamic PGE2 in mice. Scand J
Immunol 1991;34:179-83.
17. ZIMLICHMAN S, DANTON A, NATNAN J, MOZES G. Se-
rum amyloid A, an acute phase protein, inhibits platelet activation.
J Lab Clin Med 1990;116:180-6.
18. MARHAUG G, HARKLAN L, OLSEN B, HUSBY G, HUSE-
BEKK A, WAN H. Serum amyloid A protein in acute myocar-
dial infarction. Acta Med Scand 1986;220:303-6.
19. RAY A, RAY BK. A novel cis-acting element is essential for cyto-
kine-mediated transcriptional induction of the serum amyloid A
gene in nonhepatic cells. Mol Cell Biol 1996;16:1584-94.
20. SHAINKIN-KESTENBAUM R, WINKIKOFF Y, CRISTAL
N. Serum amyloid A concentrations during the course of acute
ischaemic heart disease. J Clin Pathol 1986;39:635-7.
21. FISHER M. Increased excretion of immunoreactive thromboxane
B2 in cerebral ischemia. Stroke 1985;16:10-4.
22. CASL MT, GRUBB A. A rapid enzyme-linked immunosorbent
assay for serum amyloid A using sequence-specific antibodies. Ann
Clin Biochem 1993;30:278-86.
23. ILZECKA J. Certain serum acute phase reactants in cerebrovascu-
lar brain lesions. Neurol Neurochir Pol 1997;31:695-704.
24. ILZECKA J , DOBOSZ B. Acute phase proteins ∑ alpha 1-acid
glycoprotein (AGP) and alpha 1 antichymotrypsin (ACT) in se-
rum of patients with cerebral ischemic stroke. Neurol Neurochir
Pol 1998;32:495-9.
25. HORNIG CR. Changes in CSF blood brain barrier parameters
in ischaemic cerebral infarction. J Neurol 1983;229:11-7.
J. Iłzecka and Z. Stelmasiak Serum amyloid A protein in cerebral infarction
Acta clin Croat, Vol. 39, No. 3, 2000 145
Saæetak
PROGNOSTI»KA VRIJEDNOST PRA∆ENJA RAZINE SERUMSKOG PROTEINA AMILOID A U
BOLESNIKA S MOÆDANIM INFARKTOM
J. Iłzecka i Z. Stelmasiak
Serumski protein amiloid A (SAA) je plazmatski protein akutne faze koji raste u odgovoru na tkivno oπteÊenje. Cilj ovoga
ispitivanja bio je istraæiti SAA u krvi bolesnika s moædanim infarktom. Ispitivanje je obuhvatilo 60 osoba, od toga 45 bolesnika
s cerebralnim infarktom i 15 kontrolnih osoba. SAA je mjeren pomoÊu metode ELISA, i to 1., 3., 7. i 14. dana nakon nastupa
ishemijskog moædanog udara. Poviπenje SAA zabiljeæeno je do 3. dana, nakon Ëega je uslijedilo sniæavanje njegove razine
ukoliko nije bilo infektivnih komplikacija. Koncentracija SAA bila je statistiËki znaËajno poviπena 1., 3., 7. i 14. dana (p<0,05),
meutim, taj je porast bio veÊi u skupini bolesnika s teæim kliniËkim manifestacijama bolesti. StatistiËki znaËajno poviπenje
SAA zabiljeæeno je do 14. dana u bolesnika s prateÊim infektivnim procesom. Ispitivanje je pokazalo da koncentracija SAA
ovisi o kliniËkoj teæini ishemijskog udara. SAA je osjetljiv rani pokazatelj moguÊih infektivnih komplikacija.
KljuËne rijeËi: moædani infarkt, komplikacije; moædani infarkt, krv; amiloidni protein SAA, analiza; infekcija, komplikacije
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